Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 8/20 | 0.52 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5415087 | 0.86 | KDM4E (0.55) | KDM4ESMN1; SMN2NPC1PKMRAB9A | |
| SCHEMBL5419706 | 0.84 | KDM4E (0.52) | KDM4ESMN1; SMN2NPC1PKMRAB9A | |
| SCHEMBL5418844 | 0.84 | KDM4E (0.52) | KDM4ESMN1; SMN2NPC1PKMRAB9A | |
| SCHEMBL316219 | 0.84 | SMN1; SMN2 (0.60) | KDM4ESMN1; SMN2NPC1PKMRAB9A | |
| SCHEMBL5423200 | 0.83 | KDM4E (0.49) | KDM4ESMN1; SMN2NPC1PKMRAB9A | |
| SCHEMBL14416785 | 0.82 | KDM4E (0.51) | KDM4ESMN1; SMN2NPC1PKMRAB9A | |
| SCHEMBL6986405 | 0.81 | KDM4E (0.50) | KDM4ESMN1; SMN2NPC1PKMRAB9A | |
| SCHEMBL5417119 | 0.80 | KDM4E (0.49) | KDM4ESMN1; SMN2NPC1PKMRAB9A | |
| SCHEMBL5425939 | 0.80 | APP (0.51) | KDM4ESMN1; SMN2NPC1PKMRAB9A | |
| SCHEMBL14409229 | 0.80 | APP (0.51) | KDM4ESMN1; SMN2NPC1PKMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208066-A1 | ER-beta-selective ligands | BARLAAM BERNARD | 2007-09-06 | — | — | US | disclosed |
| US-20070208066-A1 | ER-beta-selective ligands | BARLAAM BERNARD | 2007-09-06 | — | — | US | disclosed |
| US-20070208066-A1 | ER-beta-selective ligands | BARLAAM BERNARD | 2007-09-06 | — | — | US | disclosed |
| US-20060111408-A1 | Therapeutic benzothiazole compounds | BARLAAM BERNARD | 2006-05-25 | — | — | US | disclosed |
| US-7045539-B2 | Therapeutic benzoxazole compounds | ASTRAZENECA AB (SE) | 2006-05-16 | — | — | US | disclosed |
| US-20040102435-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | disclosed |
| EP-1345914-A1 | THERAPEUTIC COMPOUNDS | AstraZeneca AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002051821-A1 | THERAPEUTIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102435-A1 | Therapeutic compounds | ESRRA, ESRRG, ESR2 | KDM4E 2759/4885SMN1; SMN2 1899/4885NPC1 2588/4885 |
| US-20070208066-A1 | ER-beta-selective ligands | ESR2, ESRRG, ESRRA | KDM4E 2761/4885SMN1; SMN2 1878/4885NPC1 2976/4885 |
| US-20060111408-A1 | Therapeutic benzothiazole compounds | ESR1, ESR2, ESRRG | KDM4E 1759/4885SMN1; SMN2 2412/4885NPC1 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.